articleThe Lancet OncologyJul 5, 2022GREEN OA

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

City Of Hope National Medical Center · Spinal Cord Injury BC · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

419
total citations
FWCI
39.73
Percentile
100%
References
28
Citations per year

Authors

20

Topics & keywords

Keywords
  • Medicine
  • Follicular lymphoma
  • Refractory (planetary science)
  • Internal medicine
  • Clinical endpoint
  • Progressive disease
  • CD20
  • Follicular phase
No related works found for this paper.

Funding